Quality of Life of Adult Cancer Survivors Who Have Undergone a Previous Bone Marrow or Peripheral Stem Cell Transplant for a Childhood Hematologic Cancer
Study Details
Study Description
Brief Summary
RATIONALE: Studying quality of life in cancer survivors may help determine the long-term effects of hematologic cancer and may help improve the quality of life for future cancer survivors.
PURPOSE: This clinical trial is studying the quality of life of adult cancer survivors who have undergone a previous bone marrow or peripheral stem cell transplant for a childhood hematologic cancer.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
OBJECTIVES:
-
Determine the extent to which adult cancer survivors who have undergone prior bone marrow or peripheral blood stem cell transplantation for a pediatric hematologic malignancy require ongoing health care and whether these needs change with increasing time after transplantation.
-
Correlate physical capabilities, body image, physical limitations, including sexuality issues which alter or influence lifestyle, with time after transplantation in these patients.
-
Determine whether cognitive abilities relative to memory and neurobehavioral ratings change with increasing time after transplantation in these patients.
-
Correlate social and relationship abilities with length of time after transplantation in these patients.
OUTLINE: Patients and siblings complete a self-report quality of life questionnaire, including outcome assessments of neuroendocrine function, cognitive abilities, physical capability, and psychosocial behavior.
PROJECTED ACCRUAL: Approximately 750 patients (375 adult cancer survivors [case group] and 375 siblings [control group]) will be accrued for this study within 7 years.
Study Design
Outcome Measures
Primary Outcome Measures
- Neuroendocrine status of disease-free childhood transplant patients at 5 years after transplant and ≥ age 18 []
- Cognitive capability of disease-free childhood transplant patients at 5 years after transplant and ≥ age 18 []
- Physical capability of disease-free childhood transplant patients at 5 years after transplant and ≥ age 18 []
- Psychosocial status of disease-free childhood transplant patients at 5 years after transplant and ≥ age 18 []
Eligibility Criteria
Criteria
DISEASE CHARACTERISTICS:
-
Case group
-
Previously treated with an allogeneic, unrelated, syngeneic, or autologous bone marrow or peripheral blood stem cell transplantation for a hematologic malignancy ≥ 5 years ago while enrolled on 1 of the following protocols:
-
FHCRC-160.06
-
FHCRC-179.07T
-
FHCRC-446.03T
-
FHCRC-661.04
-
FHCRC-697.00
-
FHCRC-796.00
-
FHCRC-843.00
-
Disease-free survivor
-
Under 18 years of age at time of transplantation
-
Any prior preparative regimen allowed
-
Control group
-
Sex-matched sibling within 5 years of patient's age*
-
No chronic illnesses (e.g., cancer, diabetes, or asthma) that require medication
-
No allergies that limit physical activity NOTE: *If such a sibling is not available, but another sibling is available, then that sibling would be asked to nominate a friend or relative of the same gender as the patient who is also within 5 years of the patient's age; the patient must consent in order for the control subject to participate
PATIENT CHARACTERISTICS:
Age
-
See Disease Characteristics
-
18 and over
Performance status
- Not specified
Life expectancy
- Not specified
Hematopoietic
- Not specified
Hepatic
- Not specified
Renal
- Not specified
Other
- Must be able to speak, read, and write English
PRIOR CONCURRENT THERAPY:
Biologic therapy
- See Disease Characteristics
Chemotherapy
- Not specified
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- Not specified
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Fred Hutchinson Cancer Research Center | Seattle | Washington | United States | 98109-1024 |
Sponsors and Collaborators
- Fred Hutchinson Cancer Center
- National Cancer Institute (NCI)
Investigators
- Principal Investigator: Jean E. Sanders, MD, Fred Hutchinson Cancer Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 1098.00
- FHCRC-1098.00
- CDR0000434793